Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis)
ClinicalTrials.gov Identifier: NCT04940065
Novartis Reference Number: COMB157G1401
Last Update: Jan 17, 2023
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Study Description
This study is an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
Interventions
Eligibility Criteria
Inclusion Criteria:
Patients must provide written consent to cooperate in this study before the start of treatment with Kesimpta
Patients using Kesimpta for the first time for the following indication Indication: prevention of relapses and and prevention of physical disability progression in the following patients
Relapsing-remitting MS
Active SPMS
Exclusion Criteria:
Patients with a history of treatment with a drug containing the same ingredient as Kesimpta (investigational drug or post-marketing clinical study drug)
Patients with a history of hypersensitivity to any of the Kesimpta ingredients
Study Locations
Contacts
Have a question?
Call 1-888-669-6682 or email [email protected]